Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 9Gynecologic 2Genitourinary 2NET 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Carcinoma 2Kidney Neoplasms 1Hormone Refractory Prostate Cancer 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 14Paclitaxel 13Prednisone 11Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7atezolizumab 6Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5cemiplimab 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × epothilone B × Genitourinary × Clear all
NCT00035113 2017-02-09

EPO906 Therapy in Patients With Prostate Cancer

Novartis

Phase 2 Completed
48 enrolled
Genitourinary

Carcinoma, Neoplasms, Prostatic Neoplasms

NCT00035243 2012-04-17

EPO906 Therapy in Patients With Advanced Kidney Cancer

Novartis

Phase 2 Completed
53 enrolled
Genitourinary

Carcinoma, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡